These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 19022547)

  • 1. Baseline characteristics of participants in the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial.
    Bostom AG; Carpenter MA; Hunsicker L; Jacques PF; Kusek JW; Levey AS; McKenney JL; Mercier RY; Pfeffer MA; Selhub J;
    Am J Kidney Dis; 2009 Jan; 53(1):121-8. PubMed ID: 19022547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale and design of the Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) trial.
    Bostom AG; Carpenter MA; Kusek JW; Hunsicker LG; Pfeffer MA; Levey AS; Jacques PF; McKenney J;
    Am Heart J; 2006 Sep; 152(3):448.e1-7. PubMed ID: 16923411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aspirin Use and Incident Cardiovascular Disease, Kidney Failure, and Death in Stable Kidney Transplant Recipients: A Post Hoc Analysis of the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial.
    Dad T; Tighiouart H; Joseph A; Bostom A; Carpenter M; Hunsicker L; Kusek JW; Pfeffer M; Levey AS; Weiner DE
    Am J Kidney Dis; 2016 Aug; 68(2):277-286. PubMed ID: 26947217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B-Vitamin Therapy for Kidney Transplant Recipients Lowers Homocysteine and Improves Selective Cognitive Outcomes in the Randomized FAVORIT Ancillary Cognitive Trial.
    Scott TM; Rogers G; Weiner DE; Livingston K; Selhub J; Jacques PF; Rosenberg IH; Troen AM
    J Prev Alzheimers Dis; 2017; 4(3):174-182. PubMed ID: 29182708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Hyperuricemia on Long-term Outcomes of Kidney Transplantation: Analysis of the FAVORIT Study.
    Kalil RS; Carpenter MA; Ivanova A; Gravens-Mueller L; John AA; Weir MR; Pesavento T; Bostom AG; Pfeffer MA; Hunsicker LG
    Am J Kidney Dis; 2017 Dec; 70(6):762-769. PubMed ID: 28801121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial.
    Jamison RL; Hartigan P; Kaufman JS; Goldfarb DS; Warren SR; Guarino PD; Gaziano JM;
    JAMA; 2007 Sep; 298(10):1163-70. PubMed ID: 17848650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial.
    Bostom AG; Carpenter MA; Kusek JW; Levey AS; Hunsicker L; Pfeffer MA; Selhub J; Jacques PF; Cole E; Gravens-Mueller L; House AA; Kew C; McKenney JL; Pacheco-Silva A; Pesavento T; Pirsch J; Smith S; Solomon S; Weir M
    Circulation; 2011 Apr; 123(16):1763-70. PubMed ID: 21482964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Albuminuria and Allograft Failure, Cardiovascular Disease Events, and All-Cause Death in Stable Kidney Transplant Recipients: A Cohort Analysis of the FAVORIT Trial.
    Weiner DE; Park M; Tighiouart H; Joseph AA; Carpenter MA; Goyal N; House AA; Hsu CY; Ix JH; Jacques PF; Kew CE; Kim SJ; Kusek JW; Pesavento TE; Pfeffer MA; Smith SR; Weir MR; Levey AS; Bostom AG
    Am J Kidney Dis; 2019 Jan; 73(1):51-61. PubMed ID: 30037726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitive dysfunction and depression in adult kidney transplant recipients: baseline findings from the FAVORIT Ancillary Cognitive Trial (FACT).
    Troen AM; Scott TM; D'Anci KE; Moorthy D; Dobson B; Rogers G; Weiner DE; Levey AS; Dallal GE; Jacques PF; Selhub J; Rosenberg IH;
    J Ren Nutr; 2012 Mar; 22(2):268-276.e3. PubMed ID: 22153382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized placebo-controlled trial assessing a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on plasma asymmetric dimethylarginine concentration in mild to moderate CKD.
    Nanayakkara PW; Kiefte-de Jong JC; ter Wee PM; Stehouwer CD; van Ittersum FJ; Olthof MR; Teerlink T; Twisk JW; van Guldener C; Smulders YM
    Am J Kidney Dis; 2009 Jan; 53(1):41-50. PubMed ID: 18786751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial.
    Albert CM; Cook NR; Gaziano JM; Zaharris E; MacFadyen J; Danielson E; Buring JE; Manson JE
    JAMA; 2008 May; 299(17):2027-36. PubMed ID: 18460663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Folic Acid Therapy on the Progression of Chronic Kidney Disease: The Renal Substudy of the China Stroke Primary Prevention Trial.
    Xu X; Qin X; Li Y; Sun D; Wang J; Liang M; Wang B; Huo Y; Hou FF;
    JAMA Intern Med; 2016 Oct; 176(10):1443-1450. PubMed ID: 27548766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homocysteine lowering and cognition in CKD: the Veterans Affairs homocysteine study.
    Brady CB; Gaziano JM; Cxypoliski RA; Guarino PD; Kaufman JS; Warren SR; Hartigan P; Goldfarb DS; Jamison RL
    Am J Kidney Dis; 2009 Sep; 54(3):440-9. PubMed ID: 19628319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum Phosphorus and Risk of Cardiovascular Disease, All-Cause Mortality, or Graft Failure in Kidney Transplant Recipients: An Ancillary Study of the FAVORIT Trial Cohort.
    Merhi B; Shireman T; Carpenter MA; Kusek JW; Jacques P; Pfeffer M; Rao M; Foster MC; Kim SJ; Pesavento TE; Smith SR; Kew CE; House AA; Gohh R; Weiner DE; Levey AS; Ix JH; Bostom A
    Am J Kidney Dis; 2017 Sep; 70(3):377-385. PubMed ID: 28579423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial.
    Ebbing M; Bleie Ø; Ueland PM; Nordrehaug JE; Nilsen DW; Vollset SE; Refsum H; Pedersen EK; Nygård O
    JAMA; 2008 Aug; 300(7):795-804. PubMed ID: 18714059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Vitamin B
    Li Y; Spence JD; Wang X; Huo Y; Xu X; Qin X
    Am J Kidney Dis; 2020 Mar; 75(3):325-332. PubMed ID: 31629573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial.
    Toole JF; Malinow MR; Chambless LE; Spence JD; Pettigrew LC; Howard VJ; Sides EG; Wang CH; Stampfer M
    JAMA; 2004 Feb; 291(5):565-75. PubMed ID: 14762035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases.
    Stanger O; Herrmann W; Pietrzik K; Fowler B; Geisel J; Dierkes J; Weger M
    Z Kardiol; 2004 Jun; 93(6):439-53. PubMed ID: 15252738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale, design and baseline characteristics of a large, simple, randomized trial of combined folic acid and vitamins B6 and B12 in high-risk patients: the Heart Outcomes Prevention Evaluation (HOPE)-2 trial.
    Lonn E; Held C; Arnold JM; Probstfield J; McQueen M; Micks M; Pogue J; Sheridan P; Bosch J; Genest J; Yusuf S;
    Can J Cardiol; 2006 Jan; 22(1):47-53. PubMed ID: 16450017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Folic acid and B vitamins improve hyperhomocysteinemia-induced cardiovascular risk profile in renal transplant recipients.
    Manrique J; Errasti P; Orbe J; Páramo JA; Rodríguez JA
    J Thromb Haemost; 2007 May; 5(5):1072-6. PubMed ID: 17461937
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.